BioCentury | Aug 14, 2020
Finance

Non-European venture investment in European biotech is on the rise

European biotechs are seeing more participation by non-European investors in venture rounds than they’ve seen in the last three years, and the median size of the financings has outstripped solely domestic rounds. BioCentury analyzed 133 European...
BioCentury | Aug 14, 2020
Deals

EU closing in on COVID-19 vaccine deals with J&J, GSK-Sanofi as COVAX works toward equitable access

The European Commission is close to securing access to two COVID-19 vaccines for its member states. On Thursday, the EU reached a preliminary agreement with J&J for 200 million doses of its adenovirus vector vaccine, after...
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a return. Private companies working in the space have long struggled to raise venture money. “Women’s health,...
BioCentury | Aug 11, 2020
Finance

AI play Atomwise to build internal pipeline with $123M series B

After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its own pipeline.  Since its 2012...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which is focused on autoimmune, alloimmune...
BioCentury | Aug 11, 2020
Product Development

Charting a path to COVID-19 testing that supports a return to normalcy

A panel of diagnostics leaders points to open questions and infrastructure gaps limiting what society is getting out of COVID-19 testing, and how the lessons learned could reach beyond the pandemic. In an Aug. 5 webinar,...
BioCentury | Aug 8, 2020
Product Development

Data sharing in and after COVID, with Takeda’s Anne Heatherington: a BioCentury podcast

Among the barriers broken by biopharmas during COVID-19 is the concept of data sharing, an idea far from standard practice in the industry, gaining life due to the gravity and urgency of the pandemic. Proponents...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

The growing demand for asymptomatic COVID-19 testing is shifting the conversation from one-time diagnosis to ongoing screening, and from single results to population outcomes. Companies moving the ball forward for early detection of cancer, some...
BioCentury | Aug 8, 2020
Product Development

Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
Items per page:
1 - 10 of 6990